20 completed, 5 terminated, 4 withdrawn, 3 recruiting. 36 Phase 3, 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 36 | Completed 20, Terminated 5, Withdrawn 4, Recruiting 3, Unknown 2, Active not recruiting 1, Not yet recruiting 1 |
| Phase 2 | 5 | Completed 2, Terminated 2, Withdrawn 1 |
Follow Alteplase: new trials by email Literature Review of Alteplase trials Research Report on Alteplase
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Reduced-Dose Thrombolysis in Intermediate-Risk Pulmonary Embolism With High-Risk Features Alteplase, Standard Anticoagulation - Pulmonary Embolism | Phase 3 | Not yet recruiting | China National Center for Cardiovascular Diseases | 270 | 2026-11-01 | 2026-11-04 |
| INtra-arterial AltEplase folloWing successfuL reperfusIoN After mEchanical Thrombectomy Alteplase, Endovascular thrombectomy - Stroke, Acute Ischemic, Large Vessel Occlusion | Phase 3 | Recruiting | 115 People's Hospital | 416 | 2026-08-01 | 2026-09-25 |
| Efficacy and Safety of Tenecteplase Bridging Mechanical Thrombectomy for Acute Large Vessel Occlusion Stroke Tenecteplase, Alteplase - Stroke, Ischemic, Stroke, Acute | Phase 3 | Recruiting | Xuanwu Hospital, Beijing | 850 | 2025-12-25 | 2026-04-09 |
| Thrombolysis in Factor Xa-inhibitors Trial thrombolysis therapy - Stroke, Stroke (in Patients With Atrial Fibrillation) | Phase 3 | Recruiting | Guri Hagberg | 300 | 2025-03-14 | 2026-11-04 |
| Trial of Reduced Alteplase Dose for Parapneumonic Effusion (TRAPPE) Tissue Plasminogen Activator - Pleural Infection | Phase 2 / Phase 3 | Completed | Chinese University of Hong Kong | 30 | 2024-11-01 | 2026-10-23 |
| Intra-arterial Alteplase for Acute Ischemic Stroke After Mechanical Thrombectomy Alteplase - Stroke, Acute Ischemic | Phase 3 | Completed | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 324 | 2023-08-01 | 2026-08-12 |
| Thrombolysis Treated With TNK-tPA in Acute Ischemic Stroke Patients （3T Stroke-Ⅲ） Alteplase, Tenecteplase - Acute Ischemic Stroke | Phase 3 | Unknown | Beijing Tiantan Hospital | 1630 | 2022-10-26 | 2023-02-27 |
| A Study of r-PA Treating Patients With Acute Ischemic Stroke（RAISE） Injection of recombinant human tissue plasminogen kinase derivatives, Recombinant human tissue plasminogen activator - Acute Ischemic Stroke | Phase 3 | Completed | Angde Biotech Pharmaceutical Co., Ltd. | 1412 | 2022-03-21 | 2024-03-04 |
| Pulmonary Embolism International THrOmbolysis Study-3 Alteplase, Placebo - Pulmonary Embolism | Phase 3 | Active not recruiting | Assistance Publique - Hôpitaux de Paris | 800 | 2021-08-04 | 2026-07-01 |
| A Study in Chinese Patients to Compare How Tenecteplase and Alteplase Given After a Stroke Improve Recovering of Physical Activity tenecteplase, alteplase - Stroke | Phase 3 | Completed | Boehringer Ingelheim | 1489 | 2021-06-22 | 2024-12-10 |
| 24 Hours Treatment with Alteplase in Patients with Ischemic Stroke Alteplase - Stroke | Phase 3 | Completed | Second Affiliated Hospital, Zhejiang University, School of Medicine | 372 | 2021-06-21 | 2025-03-05 |
| Massive Pulmonary Embolism: Trial of Non-immunogenic Recombinant Staphylokinase VS Alteplase FORPE Recombinant nonimmunogenic staphylokinase, Alteplase - Massive Pulmonary Embolism | Phase 3 | Completed | Supergene, LLC | 310 | 2020-12-15 | 2025-04-02 |
| Impact of Tissue Plasminogen Activator (tPA) Treatment for an Atypical Acute Respiratory Distress Syndrome (COVID-19) Tissue plasminogen activator, Ringer solution - Acute Respiratory Distress Syndrome | Phase 3 | Withdrawn | Negovsky Reanimatology Research Institute | 2020-10-15 | 2021-03-12 | |
| Efficacy and Safety of CUSA-081 in the Restoration of Central Venous Access Device (CVAD) Functionality CUSA-081, Placebo, Alteplase - Catheter Occlusion, Thrombosis | Phase 3 | Terminated | Chiesi Farmaceutici S.p.A. | 462 | 2020-02-12 | 2024-08-23 |
| Alteplase Compared to Tenecteplase in Patients With Acute Ischemic Stroke Tenecteplase, Alteplase - Stroke, Acute, Thromboses, Intracranial | Phase 3 | Completed | University of Calgary | 1600 | 2019-12-10 | 2023-05-12 |
| The Norwegian Tenecteplase Stroke Trial 2 Tenecteplase, Alteplase - Stroke, Acute, Cerebrovascular Disorders | Phase 3 | Terminated | Haukeland University Hospital | 201 | 2019-10-28 | 2025-03-03 |
| Pediatric High-Risk Deep Venous Thrombosis Lytic Outcomes Trial Recombinant tissue plasminogen activator (rt-PA), Standard Anticoagulation Therapy - Deep Vein Thrombosis, Post-Thrombotic Syndrome | Phase 3 | Withdrawn | University of Colorado, Denver | 2018-07-01 | 2018-08-10 | |
| A Phase III Randomized, Blind, Double Dummy, Multicenter Study Assessing the Efficacy and Safety of IV THrombolysis (Alteplase) in Patients With acutE Central retInal Artery Occlusion Alteplase, acetylsalicylic acid, Placebo Oral Tablet - Central Retinal Artery Occlusion | Phase 3 | Completed | Nantes University Hospital | 70 | 2018-06-08 | 2024-01-24 |
| Study of rhPro-UK in Patients With Acute Ischaemic Stroke in 4.5 Hours After Stroke Onset(PROST) Recombinant human urokinase, Alteplase - Acute Ischaemic Stroke | Phase 3 | Completed | Tasly Biopharmaceuticals Co., Ltd. | 674 | 2018-05-18 | 2020-06-22 |
| Tirofiban for Patients Treated With Alteplase Tirofiban, Alteplase - Ischemic Stroke | Phase 2 / Phase 3 | Terminated | Capital Medical University | 30 | 2017-12-16 | 2020-09-09 |
Showing 20 of 36. Sign in to see all of them.
Ischemic Stroke (12) · Stroke (11) · Pulmonary Embolism (4) · Intracranial Thrombosis (3) · Thrombosis (3) · Cerebral Infarction (2) · Intracranial Hemorrhages (2) · Postthrombotic Syndrome (2) · Venous Thrombosis (2) · Bites and Stings (1) · Brain Ischemia (1) · COVID-19 (1) · Cerebral Hemorrhage (1) · Cerebrovascular Disorders (1) · Macular Degeneration (1)
Boehringer Ingelheim (3) · Johns Hopkins University (2) · Supergene, LLC (2) · 115 People's Hospital (1) · Angde Biotech Pharmaceutical Co., Ltd. (1) · Assistance Publique - Hôpitaux de Paris (1) · Azienda U.S.L. 1 di Massa e Carrara (1) · Beijing Tiantan Hospital (1) · Boston Scientific Corporation (1) · Capital Medical University (1) · Chiesi Farmaceutici S.p.A. (1) · China National Center for Cardiovascular Diseases (1) · Chinese University of Hong Kong (1) · Genentech, Inc. (1) · Guri Hagberg (1)
China (12) · United States (7) · Canada (5) · Spain (5) · France (4) · Germany (4) · United Kingdom (4) · Belgium (3) · Norway (3) · Switzerland (3) · Denmark (2) · Hungary (2) · Israel (2) · Netherlands (2) · Poland (2)
Daniel F. Hanley, MD (2) · Sergey S Markin, MD, PhD (2) · Alberto Conti, MD (1) · Alexander I Kirienko, MD, PhD (1) · Barry S Weinstock, MD (1) · Bijoy K Menon, MD (1) · Changming Xiong, Prof. (1) · Charles BL Majoie, MD, PhD (1) · Christian Gerloff, MD (1) · Clive Kearon, MB, MRCP, FRCP(C), PhD (1) · David SC Hui, MD (1) · E Houdart, MD, PhD (1)
PMID 26387127, PMID 37830342, PMID 39500603, PMID 16763187, PMID 20047905, PMID 21737309, PMID 22340437, PMID 23537968, PMID 25628404, PMID 25638754, PMID 26243227, PMID 26315743, PMID 27913777, PMID 28081952, PMID 28174327, PMID 28425349, PMID 28780236, PMID 28842449, PMID 28887375, PMID 29211671, PMID 29766770, PMID 29998337, PMID 30586751, PMID 30602354, PMID 30699446, PMID 30739747, PMID 31009339, PMID 31161343, PMID 31177984, PMID 31354089, PMID 31571176, PMID 31592728, PMID 31824412, PMID 31843251, PMID 32026447, PMID 32421159, PMID 32467323, PMID 32511749, PMID 32631157, PMID 33324925, PMID 33445952, PMID 33613422, PMID 33657675, PMID 33980046, PMID 34414292, PMID 34418399, PMID 34433305, PMID 34564893, PMID 34782419, PMID 34937780
2018 (2), 2019 (1), 2023 (1), U01HL088476 (1), U01NS062851 (1), U01NS080824 (1)